Profile data is unavailable for this security.
About the company
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The Company's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.
- Revenue in USD (TTM)1.06m
- Net income in USD-114.99m
- Incorporated2018
- Employees170.00
- LocationCentury Therapeutics Inc3675 Market StPHILADELPHIA 19104United StatesUSA
- Phone+1 (215) 981-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.centurytx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Somalogic Inc | 85.75m | -82.04m | 723.69m | 320.00 | -- | 1.27 | -- | 9.14 | -0.4517 | -0.4517 | 0.4717 | 3.39 | 0.1803 | 3.51 | 4.66 | 267,956.30 | -17.25 | -- | -18.19 | -- | 54.67 | -- | -95.68 | -- | 24.42 | -- | 0.00 | -- | 46.05 | -- | -65.14 | -- | -- | -- |
| Dice Therapeutics Inc | 1.13m | -59.48m | 747.38m | 56.00 | -- | 2.64 | -- | 692.88 | -1.58 | -1.58 | 0.03 | 7.72 | -- | -- | -- | 24,456.52 | -- | -- | -- | -- | -- | -- | -5,287.47 | -- | -- | -- | 0.0082 | -- | 30.36 | -- | -106.24 | -- | -- | -- |
| Nuvalent Inc | 0.00 | -57.10m | 751.28m | 48.00 | -- | 3.14 | -- | -- | -1.70 | -1.70 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -39.07 | -- | -40.63 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -218.34 | -- | -- | -- |
| HeadHunter Group PLC | 294.20m | 84.43m | 761.05m | 1.36k | 9.22 | 13.94 | 7.28 | 2.59 | 1.63 | 1.63 | 5.68 | 1.08 | 0.8629 | -- | 147.61 | 216,164.60 | 25.15 | 14.07 | 41.47 | 20.17 | -- | -- | 29.15 | 24.38 | -- | 16.58 | 0.7048 | 38.73 | 92.80 | 33.69 | 208.22 | 165.52 | 14.19 | -- |
| Century Therapeutics Inc | 1.06m | -114.99m | 770.94m | 170.00 | -- | 1.72 | -- | 644.13 | -3.58 | -3.58 | 0.0237 | 6.71 | 0.0025 | -- | -- | 6,223.53 | -27.50 | -- | -28.69 | -- | -- | -- | -10,868.53 | -- | -- | -81.77 | 0.0253 | -- | -- | -- | -78.86 | -- | -- | -- |
| Forrester Research, Inc. | 525.08m | 30.57m | 792.79m | 1.78k | 27.20 | -- | 15.16 | 1.56 | 1.59 | 1.59 | 27.21 | -- | -- | -- | -- | 294,823.70 | -- | 2.32 | -- | 4.37 | 58.80 | 58.92 | 5.82 | 2.75 | -- | 16.44 | -- | 48.69 | 10.10 | 8.68 | 148.69 | 7.08 | 21.02 | -- |
| SP Plus Corp | 1.39bn | 46.50m | 806.29m | 10.80k | 16.61 | 3.39 | 11.20 | 0.6071 | 2.18 | 2.18 | 64.81 | 10.65 | 1.26 | -- | 10.45 | 128,296.30 | 4.46 | 0.25 | 6.25 | 0.3404 | 15.09 | 13.03 | 3.55 | 0.1932 | -- | 4.85 | 0.5553 | -- | 8.31 | -6.13 | 118.34 | 6.53 | -10.59 | -- |
| POINT Biopharma Global Inc | 0.00 | -56.50m | 808.42m | 72.00 | -- | 3.39 | -- | -- | -0.6264 | -0.6264 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -38.75 | -- | -42.17 | -- | -- | -- | -- | -- | -- | -956.29 | 0.00 | -- | -- | -- | -243.25 | -- | -- | -- |
| Viad Corp | 913.74m | -30.14m | 812.89m | 3.51k | -- | -- | 28.12 | 0.9388 | -1.48 | -1.45 | 44.31 | 6.06 | 0.8762 | 66.27 | 10.01 | 260,175.10 | -1.48 | -6.64 | -2.05 | -9.74 | 4.40 | 2.30 | -1.69 | -6.92 | 0.9668 | 0.8039 | 0.6912 | -- | 22.12 | -15.89 | 72.69 | -- | 3.07 | -- |
| Relmada Therapeutics Inc | 0.00 | -143.28m | 817.25m | 10.00 | -- | 4.09 | -- | -- | -7.19 | -7.19 | 0.00 | 7.16 | 0.00 | -- | -- | 0.00 | -86.92 | -- | -95.03 | -- | -- | -- | -- | -- | -- | -83.95 | 0.00 | -- | -- | -- | -111.50 | -- | -- | -- |
| Kelly Services, Inc. | 5.00bn | 81.70m | 831.41m | 7.40k | 10.95 | 0.6649 | 7.92 | 0.1695 | 2.04 | 2.04 | 127.31 | 33.60 | 1.85 | -- | 3.57 | 675,702.70 | 2.80 | 2.41 | 4.67 | 3.85 | 19.29 | 18.08 | 1.51 | 1.14 | -- | -- | 0.0002 | 14.07 | 8.72 | -1.43 | 314.86 | 5.53 | -2.48 | -- |
| Instil Bio Inc | 0.00 | -187.78m | 835.24m | 412.00 | -- | 1.69 | -- | -- | -1.46 | -1.46 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -29.78 | -- | -31.12 | -- | -- | -- | -- | -- | -- | -147.27 | 0.00 | -- | -100.00 | -- | -315.48 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2022 | 7.33m | 12.45% |
| Casdin Capital LLCas of 31 Mar 2022 | 3.21m | 5.45% |
| BlackRock Fund Advisorsas of 30 Jun 2022 | 1.18m | 2.00% |
| Federated Global Investment Management Corp.as of 31 Mar 2022 | 1.16m | 1.98% |
| Deep Track Capital LPas of 30 Jun 2022 | 924.64k | 1.57% |
| RA Capital Management LPas of 31 Mar 2022 | 914.09k | 1.55% |
| The Vanguard Group, Inc.as of 30 Jun 2022 | 891.40k | 1.52% |
| Avidity Partners Management LPas of 31 Mar 2022 | 865.00k | 1.47% |
| Marshall Wace LLPas of 31 Mar 2022 | 701.34k | 1.19% |
| Octagon Capital Advisors LPas of 31 Mar 2022 | 658.27k | 1.12% |
